Back to results
US 2021/0079031 A1Published application
New antiviral acyclonucleoside analogues
AssigneesCentre National De La Recherche Scientifique, Universite D'Orleans, NéOvirtech SAS
InventorsLuigi AGROFOGLIO, Vincent ROY, Coralie DE SCHUTTER, Maxime BESSIERES, Franck GALLARDO
Life of this patent
Estimating the term…
Abstract
The present invention concerns a compound having the following formula (I): as well as its use as a medicament, especially for its use for treating viral infections.
Claims19
A compound having the following formula (I):
- wherein:
- n is 0, 1 or 2;
- “a” is a single or a double bond;
- X1, X2, and X3 are, independently from each other, CH or N, preferably one of them being N;
- R″ is chosen from the group consisting of:
- H, NH2, and halogen atoms such as Cl;
- R is chosen from the group consisting of:
- —NRaRb groups, Ra and Rb being independently from each other H, a (C1-C6)alkyl group or a (C3-C6)cycloalkyl group;
- halogen atoms;
- and
- (C1-C6)alkoxy groups;
- R′ is a group of formula (1)
- wherein R1 and R2 are independently from each other chosen from the group consisting of:
- OH;
- (C1-C6)alkoxy groups;
- —O-A1-O-A2 groups;
- wherein A1 is an alkylene radical comprising from 1 to 6 carbon atoms, and A2 is a (C1-C20)alkyl group;
- —O-A3-O—C(═O)-A4, wherein A3 is an alkylene radical comprising from 1 to 6 carbon atoms, and A4 is a (C1-C6)alkyl group;
- —O-A5-O—C(═O)—O-A6, wherein A5 is an alkylene radical comprising from 1 to 6 carbon atoms, and A6 is a (C1-C6)alkyl group;
- or R′ is a group of formula (2):
- wherein:
- R4 is a (C6-C10)aryl group;
- R5 is a (C1-C6)alkyl group,
- R6 is chosen from the group consisting of:
- (C1-C6)alkyl groups, and (C6-C10)aryl groups,
- R3 is chosen from the group consisting of:
- H;
- (C1-C6)alkyl groups;
- -A7-OH, wherein A7 is an alkylene radical comprising from 1 to 6 carbon atoms;
- and
- -A8-O—C(═O)-A9, wherein A8 is an alkylene radical comprising from 1 to 6 carbon atoms, and A9 is a (C1-C6)alkyl group;
- as well as its pharmaceutically acceptable salts or its racemates, diastereoisomers or enantiomers,
- for use for the treatment of viral infections, in particular infections due to DNA viruses or RNA viruses.
30 more elements
A compound having the following formula (I′):
- wherein:
- n is 0, 1 or 2;
- X1, X2, and X3 are, independently from each other, CH or N, preferably one of them being N;
- R″ is chosen from the group consisting of:
- H, NH2, and halogen atoms such as Cl;
- R is chosen from the group consisting of:
- NRaRb groups, Ra and Rb being independently from each other H, a (C1-C6)alkyl group or a (C3-C6)cycloalkyl group;
- halogen atoms;
- and
- (C1-C6)alkoxy groups;
- R′ is a group of formula (1)
- wherein R1 and R2 are independently from each other chosen from the group consisting of:
- OH;
- (C1-C6)alkoxy groups;
- —O-A1-O-A2 groups;
- wherein A1 is an alkylene radical comprising from 1 to 6 carbon atoms, and A2 is a (C1-C20)alkyl group;
- —O-A3-O—C(═O)-A4, wherein A3 is an alkylene radical comprising from 1 to 6 carbon atoms, and A4 is a (C1-C6)alkyl group;
- —O-A5-O—C(═O)—O-A6, wherein A5 is an alkylene radical comprising from 1 to 6 carbon atoms, and A6 is a (C1-C6)alkyl group;
- or R′ is a group of formula (2):
- wherein:
- R4 is a (C6-C10)aryl group;
- R5 is a (C1-C6)alkyl group,
- R6 is chosen from the group consisting of:
- (C1-C6)alkyl groups, and (C6-C10)aryl groups,
- R3 is chosen from the group consisting of:
- H;
- (C1-C6)alkyl groups;
- -A7-OH, wherein A7 is an alkylene radical comprising from 1 to 6 carbon atoms;
- and
- -A8-O—C(═O)-A9, wherein A8 is an alkylene radical comprising from 1 to 6 carbon atoms, and A9 is a (C1-C6)alkyl group;
- as well as its pharmaceutically acceptable salts or its racemates, diastereoisomers or enantiomers.
28 more elements
Dependencies are inferred from the claim text.